- Previous Close
3.070 - Open
3.100 - Bid 3.190 x --
- Ask 3.210 x --
- Day's Range
3.050 - 3.280 - 52 Week Range
2.160 - 6.500 - Volume
3,949,000 - Avg. Volume
3,139,442 - Market Cap (intraday)
5.474B - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.040 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.56
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China.
www.lepubiopharma.comRecent News: 2157.HK
View More
Performance Overview: 2157.HK
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2157.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2157.HK
View MoreValuation Measures
Market Cap
5.25B
Enterprise Value
5.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.15
Price/Book (mrq)
5.33
Enterprise Value/Revenue
24.75
Enterprise Value/EBITDA
66.56
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.41%
Return on Assets (ttm)
-11.33%
Return on Equity (ttm)
-10.26%
Revenue (ttm)
205.08M
Net Income Avi to Common (ttm)
-72.62M
Diluted EPS (ttm)
-0.040
Balance Sheet and Cash Flow
Total Cash (mrq)
586.22M
Total Debt/Equity (mrq)
85.91%
Levered Free Cash Flow (ttm)
-150.46M
Research Analysis: 2157.HK
View MoreCompany Insights: 2157.HK
2157.HK does not have Company Insights